• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

统计解释 4 剂 COVID-19 疫苗在普通人群中的保护作用。

Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population.

机构信息

Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.

Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Front Public Health. 2023 Sep 22;11:1253762. doi: 10.3389/fpubh.2023.1253762. eCollection 2023.

DOI:10.3389/fpubh.2023.1253762
PMID:37808972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10556658/
Abstract

OBJECTIVES

To assess the effectiveness of four doses of the vaccine against SARS-CoV-2 in the general population and the impact of this on the severity of the disease by age group.

METHODS

By using data from the health authority public data base, we build statistical models using R and the GAMLSS library to explain the behavior of new SARS-CoV-2 infections, active COVID-19 cases, ICU bed requirement total and by age group, and deaths at the national level.

RESULTS

The four doses of vaccine and at least the interaction between the first and second doses were important explanatory factors for the protective effect against COVID-19. The for new cases per day was 0.5644 and for occupied ICU beds the is 0.9487. For occupied ICU beds for >70 years is 0.9195 and with the interaction between 4 doses as the main factor.

CONCLUSIONS

Although the increase in the number of vaccine doses did not adequately explain the decrease in the number of COVID-19 cases, it explained the decrease in ICU admissions and deaths nationwide and by age group.

摘要

目的

评估普通人群中接种四剂 SARS-CoV-2 疫苗的效果,以及按年龄组评估这对疾病严重程度的影响。

方法

我们利用卫生当局公共数据库中的数据,使用 R 和 GAMLSS 库构建统计模型,以解释新的 SARS-CoV-2 感染、活跃的 COVID-19 病例、总 ICU 床位需求和按年龄组划分的 ICU 床位需求以及全国范围内的死亡人数的行为。

结果

四剂疫苗,以及至少第一剂和第二剂之间的相互作用,是对 COVID-19 具有保护作用的重要解释因素。新发病例的日增长率为 0.5644,占用 ICU 床位的增长率为 0.9487。对于>70 岁的 ICU 床位,增长率为 0.9195,主要因素是四剂疫苗之间的相互作用。

结论

尽管疫苗接种剂量的增加并不能充分解释 COVID-19 病例的减少,但它解释了全国范围内以及按年龄组划分的 ICU 入院和死亡人数的减少。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/5ef14acf3d54/fpubh-11-1253762-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/7063da08bb13/fpubh-11-1253762-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/d74c70e2bf62/fpubh-11-1253762-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/62e6c09c909a/fpubh-11-1253762-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/5ef14acf3d54/fpubh-11-1253762-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/7063da08bb13/fpubh-11-1253762-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/d74c70e2bf62/fpubh-11-1253762-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/62e6c09c909a/fpubh-11-1253762-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdc2/10556658/5ef14acf3d54/fpubh-11-1253762-g0004.jpg

相似文献

1
Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population.统计解释 4 剂 COVID-19 疫苗在普通人群中的保护作用。
Front Public Health. 2023 Sep 22;11:1253762. doi: 10.3389/fpubh.2023.1253762. eCollection 2023.
2
Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape.通过解释性广义加性模型评估两剂疫苗接种对智利 COVID-19 病例、重症监护病房住院和死亡的减少作用。
Front Public Health. 2022 Jul 27;10:815036. doi: 10.3389/fpubh.2022.815036. eCollection 2022.
3
COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.2022 年第一季度,在欧洲 SARS-CoV-2 奥密克戎波期间,COVID-19 疫苗接种率与感染、住院、重症监护病房入院和死亡。
J Med Virol. 2023 Jan;95(1):e28131. doi: 10.1002/jmv.28131. Epub 2022 Sep 14.
4
Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.美国 2020 年 12 月至 2021 年 9 月,疫苗接种者预防 COVID-19 感染、住院和死亡人数的估计数。
JAMA Netw Open. 2022 Jul 1;5(7):e2220385. doi: 10.1001/jamanetworkopen.2022.20385.
5
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性:一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
6
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.奥密克戎 BA.4 和 BA.5 亚谱系流行期间,根据疫苗接种状态估计 COVID-19 mRNA 疫苗有效性和 COVID-19 疾病及严重程度。
JAMA Netw Open. 2023 Mar 1;6(3):e232598. doi: 10.1001/jamanetworkopen.2023.2598.
7
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.2021 年 8 月至 10 月,BNT162b2 疫苗第三剂接种与长期护理机构居民 SARS-CoV-2 感染、COVID-19 相关住院和死亡的相关性。
JAMA Netw Open. 2022 Jul 1;5(7):e2219940. doi: 10.1001/jamanetworkopen.2022.19940.
8
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州,2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
9
COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.COVID-19 疫苗对≥65 岁人群中出现症状的 SARS-CoV-2 感染、COVID-19 相关住院和死亡的有效性:基于国家登记数据链接的 2021 年 2 月至 9 月的队列研究。
PLoS One. 2022 Sep 13;17(9):e0274008. doi: 10.1371/journal.pone.0274008. eCollection 2022.
10
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.

引用本文的文献

1
The effect of COVID vaccination timing on the seroprevalence of IgG antibodies: evidence from the Guayas region of Ecuador.新冠疫苗接种时间对IgG抗体血清流行率的影响:来自厄瓜多尔瓜亚斯地区的证据。
Front Public Health. 2025 Mar 25;13:1537049. doi: 10.3389/fpubh.2025.1537049. eCollection 2025.

本文引用的文献

1
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults.在成年人中,由灭活的 SARS-CoV-2 疫苗的第二次加强针诱导的体液和细胞反应。
EBioMedicine. 2023 May;91:104563. doi: 10.1016/j.ebiom.2023.104563. Epub 2023 Apr 24.
2
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods.奥密克戎 BA.4 和 BA.5 亚谱系流行期间,根据疫苗接种状态估计 COVID-19 mRNA 疫苗有效性和 COVID-19 疾病及严重程度。
JAMA Netw Open. 2023 Mar 1;6(3):e232598. doi: 10.1001/jamanetworkopen.2023.2598.
3
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
儿童中灭活疫苗诱导的 SARS-CoV-2 变异株特异性免疫。
mBio. 2022 Dec 20;13(6):e0131122. doi: 10.1128/mbio.01311-22. Epub 2022 Nov 16.
4
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.两种免疫程序接种灭活 SARS-CoV-2 疫苗在随机 3 期临床试验中引起的免疫反应差异。
Elife. 2022 Oct 13;11:e81477. doi: 10.7554/eLife.81477.
5
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis.新冠疫苗对现实世界中关注的 SARS-CoV-2 变异株的有效性:文献综述和荟萃分析。
Emerg Microbes Infect. 2022 Dec;11(1):2383-2392. doi: 10.1080/22221751.2022.2122582.
6
Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape.通过解释性广义加性模型评估两剂疫苗接种对智利 COVID-19 病例、重症监护病房住院和死亡的减少作用。
Front Public Health. 2022 Jul 27;10:815036. doi: 10.3389/fpubh.2022.815036. eCollection 2022.
7
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.科兴疫苗加强针可提高对 Delta 和 Omicron 变异株的中和抗体和 T 细胞应答。
mBio. 2022 Aug 30;13(4):e0142322. doi: 10.1128/mbio.01423-22. Epub 2022 Aug 10.
8
Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial.成人中两种灭活新型冠状病毒疫苗免疫程序的安全性和非劣效性评估:一项随机临床试验
Vaccines (Basel). 2022 Jul 6;10(7):1082. doi: 10.3390/vaccines10071082.
9
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway.SARS-CoV-2 奥密克戎是一种具有改变的细胞进入途径的免疫逃逸变体。
Nat Microbiol. 2022 Aug;7(8):1161-1179. doi: 10.1038/s41564-022-01143-7. Epub 2022 Jul 7.
10
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体BA.2.12.1、BA.4和BA.5的中和逃逸
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.